Don't ignore those symptoms. Head and neck cancers are far more manageable, and often curable, with less aggressive treatment ...

Phenotypic variables such as smoking history and occupational exposures were significators predictors of head and neck cancer risk.

New data presented at AACR supports adding pembrolizumab before and after surgery in patients with newly diagnosed locally ...

First-line treatment with a Keytruda combo had an overall survival of 17.6 months in some with recurrent/metastatic head and ...

Immutep's eftilagimod shows a 17.6-month survival benefit in head and neck cancer. Find out how and why IMMP is continuing to ...

Pembrolizumab (Keytruda) given before and after surgery to supplement adjuvant therapy improved responses and survival in ...

The MyHPVscore test represents a successful translation of research from the laboratory to clinical practice. A Michigan ...

Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab before, during and after standard-of-care surgery had longer event-free survival without ...

The trial, which was funded by MSD and led by researchers at Washington University School of Medicine, USA, tested the drug on newly-diagnosed locally-advanced head and neck cancers. Hundreds of ...

Adding pembrolizumab before and after surgery reduced recurrence and improved response in patients with locally advanced head ...

Adding perioperative pembrolizumab to standard care can improve EFS in locally advanced head and neck cancer, data suggest.

Ending a 20-year-plus drought, Merck & Co.’s Keytruda demonstrated that its use around surgery can reduce the risk of certain ...